NO20080781L - GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer - Google Patents

GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer

Info

Publication number
NO20080781L
NO20080781L NO20080781A NO20080781A NO20080781L NO 20080781 L NO20080781 L NO 20080781L NO 20080781 A NO20080781 A NO 20080781A NO 20080781 A NO20080781 A NO 20080781A NO 20080781 L NO20080781 L NO 20080781L
Authority
NO
Norway
Prior art keywords
glepp
autoimmune
treatment
inhibitors
inflammatory diseases
Prior art date
Application number
NO20080781A
Other languages
English (en)
Norwegian (no)
Inventor
Pierre-Alain Vitte
Catherine Jorand-Lebrun
Rob Hooft Van Huijsduijnen
Patrick Gerber
Agnes Bombrun
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of NO20080781L publication Critical patent/NO20080781L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41521,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20080781A 2005-07-15 2008-02-13 GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer NO20080781L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05106547 2005-07-15
US70636505P 2005-08-08 2005-08-08
PCT/EP2006/064288 WO2007009959A1 (en) 2005-07-15 2006-07-14 Glepp-1 inhibitors in the treatment of autoimmune and/or inflammatory disorders

Publications (1)

Publication Number Publication Date
NO20080781L true NO20080781L (no) 2008-02-13

Family

ID=35423337

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080781A NO20080781L (no) 2005-07-15 2008-02-13 GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer

Country Status (24)

Country Link
US (1) US20080207722A1 (sr)
EP (1) EP1904048B1 (sr)
JP (1) JP2009501197A (sr)
KR (1) KR20080036084A (sr)
CN (1) CN101282719A (sr)
AT (1) ATE534380T1 (sr)
AU (1) AU2006271682B2 (sr)
BR (1) BRPI0613400A2 (sr)
CA (1) CA2609929A1 (sr)
CY (1) CY1112148T1 (sr)
DK (1) DK1904048T3 (sr)
EA (1) EA200800342A1 (sr)
ES (1) ES2377881T3 (sr)
HR (1) HRP20110875T1 (sr)
IL (1) IL188735A (sr)
MX (1) MX2008000665A (sr)
NO (1) NO20080781L (sr)
PL (1) PL1904048T3 (sr)
PT (1) PT1904048E (sr)
RS (1) RS52116B (sr)
SI (1) SI1904048T1 (sr)
UA (1) UA94049C2 (sr)
WO (1) WO2007009959A1 (sr)
ZA (1) ZA200710497B (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564931T3 (es) * 2009-07-30 2016-03-30 Teva Pharmaceutical Industries Ltd. Tratamiento de enfermedad de Crohn con laquinimod
WO2012149049A1 (en) * 2011-04-26 2012-11-01 Indiana University Research And Technology Corporation Tyrosine phosphatase inhibitors and uses thereof to modulate the activity of enzymes involved in the pathology of mycobacterium tuberculosis
EP3394041A1 (en) * 2015-12-22 2018-10-31 Syngenta Participations AG Microbiocidal oxadiazole derivatives
CN107936110B (zh) * 2017-11-07 2021-06-22 潍坊医学院 突变基因Nasp在狼疮性模型小鼠自身免疫病发病中的作用及机制
WO2021206787A1 (en) * 2020-04-06 2021-10-14 Purdue Research Foundation Novel n-aryl oxamic acids
US20250332138A1 (en) * 2022-01-27 2025-10-30 Vivozon, Inc. Pharmaceutical composition for preventing or treating mental disorder
CN118239851B (zh) * 2024-03-20 2025-07-25 蚌埠医科大学 一种ptpro抑制剂的制备方法及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
EP0727406B1 (de) * 1995-02-16 2001-09-05 MERCK PATENT GmbH Vinylenverbindungen und flüssigkristallines Medium
AU5347496A (en) * 1995-04-21 1996-11-07 Daiichi Pharmaceutical Co., Ltd. Ethynylthiazole derivative
FR2762514B1 (fr) * 1997-04-29 1999-10-22 Sanofi Sa Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments pour le traitement des maladies entrainant une demyelinisation
WO2003032999A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
CA2463615C (en) * 2001-10-30 2011-07-26 Applied Research Systems Ars Holding N.V. Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps)
JP2003171305A (ja) * 2001-11-30 2003-06-20 Yunie:Kk 糖尿病改善治療剤
JP2005170790A (ja) 2002-01-09 2005-06-30 Ajinomoto Co Inc N−アルキルスルフォニル置換アミド誘導体
ATE510817T1 (de) * 2002-01-29 2011-06-15 Merck Serono Sa Substituierte methylenamidderivate als modulatoren von proteintyrosinphosphatasen (ptps)
EP1603858A2 (en) 2003-03-11 2005-12-14 NeuroSearch A/S Kcnq channel modulating compounds and their pharmaceutical use
AU2004261400A1 (en) * 2003-07-21 2005-02-10 Laboratoires Serono Sa Alkynyl aryl carboxamides
WO2005007616A1 (en) 2003-07-23 2005-01-27 Warner-Lambert Company Llc Diphenylamino ketone derivatives as mek inhibitors
AU2005231980B2 (en) * 2004-04-07 2011-09-08 Merck Serono Sa 1,1'-(1,2-ethynediyl)bis-benzene derivatives as PTP 1-B inhibitors

Also Published As

Publication number Publication date
DK1904048T3 (da) 2011-12-19
WO2007009959A1 (en) 2007-01-25
EA200800342A1 (ru) 2008-08-29
EP1904048A1 (en) 2008-04-02
ES2377881T3 (es) 2012-04-02
KR20080036084A (ko) 2008-04-24
RS52116B (sr) 2012-08-31
CN101282719A (zh) 2008-10-08
US20080207722A1 (en) 2008-08-28
IL188735A0 (en) 2008-12-29
AU2006271682A1 (en) 2007-01-25
IL188735A (en) 2012-07-31
ATE534380T1 (de) 2011-12-15
PL1904048T3 (pl) 2012-04-30
CY1112148T1 (el) 2015-11-04
EP1904048B1 (en) 2011-11-23
ZA200710497B (en) 2009-04-29
MX2008000665A (es) 2008-03-13
JP2009501197A (ja) 2009-01-15
CA2609929A1 (en) 2007-01-25
AU2006271682B2 (en) 2012-07-05
HRP20110875T1 (hr) 2011-12-31
UA94049C2 (ru) 2011-04-11
BRPI0613400A2 (pt) 2011-01-11
SI1904048T1 (sl) 2012-01-31
PT1904048E (pt) 2011-12-19

Similar Documents

Publication Publication Date Title
EA200870019A1 (ru) Лактамовые соединения и способы их применения
DK2024367T3 (da) Tetrahydropyrrolopyrimidindioner og deres anvendelse som inhibitorer af human neutrofil elastase
CY1108748T1 (el) Χρηση αναστολεων της il-18 για την αντιμετωπιση και/η προληψη περιφερικων αγγειακων παθησεων
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
CY2016015I2 (el) Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων
ATE416177T1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
NO20082594L (no) Pyrimidinylbenzotiofenforbindelser
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
DK1809280T3 (da) Mitotiske kinesininhibitorer og fremgangsmåder til anvendelse deraf
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
NO20082120L (no) Behandling og forebyggelse av mikroangiopati
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
JO3676B1 (ar) مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها
NO20076405L (no) Anvendelse av 24-nor-UDCA
EP1965827A4 (en) TREATMENT OF CONDITIONS RELATED TO DEMYELINATION
CY1117251T1 (el) Μεθοδοι θεραπευτικης αντιμετωπισης της σκληροδερμιας
EP2046368A4 (en) ANTI-COCAINE COMPOSITIONS AND TREATMENT
IL188735A0 (en) Use of glepp-1 inhibitor for the menufacture of a medicament for treament of an autoimmune and/or inflamatory disorder
MX2009005550A (es) Inhibidores de fosfatasa de proteina tirosina para la promocion de la hipertrofia cardiaca fisiologica.
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
ATE481392T1 (de) Benzimidazolderivate zur behandlung entzündlicher erkrankungen
UA110918C2 (uk) Інгібітори протеїнфосфатази-1 та їх застосування
ATE552888T1 (de) Elastasehemmer bei leukämie
DE602004028497D1 (de) Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application